MTOR and leukemia: Among these, compound <b>9a</b> (LASSBio-2337) emerged as a dual pan-PI3K/mTOR inhibitor (IC<sub>50</sub>: 0.3-5.8 μM), showing cytotoxic effects in leukemia cell lines (CC<sub>50</sub>: 4.37-9.44 μM), including those with multidrug resistance (Lucena, MDR phenotype), while sparing nontumor hPBMCs.